Actively Recruiting

Age: 18Years +
All Genders
NCT04749693

Observational Study of the Use of DBLG1 System in Real Life

Led by Diabeloop · Updated on 2024-05-07

348

Participants Needed

20

Research Sites

241 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will be conducted on human subjects and is observational, prospective and uncontrolled, defined as a category 3 according to the Jardé Law (RIPH3). It is a national and multicentric study. Enrolled patients are Type 1 Diabetes (T1D) patients who receive the DBLG1 System (CE marked medical device) to be treated. Patients have their regular visits with their own clinician. No change from their usual care must and will be done, including trainings and treatment. At the end of the study, patients will keep their system for their usual care and will continue having usual follow-up visits with their clinician. Data related to their glycemia, complications and quality of life will be collected for 1 year from the beginning of their treatment. A comparison with data collected during the 2 weeks of run-in period, prior to the activation of loop mode, is planned. In case the run-in phase lasts longer than 2 weeks, data collected from the two last weeks only will be kept for analysis and comparison. The study is completed when all patients have their "end of study" file completed in the electronic Case Report Form (eCRF).

CONDITIONS

Official Title

Observational Study of the Use of DBLG1 System in Real Life

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with type 1 diabetes
  • Patients who are at least 18 years old
  • Patients with a total daily insulin dose less than 90 units
  • Patients agreeing to be treated with 100 U/mL rapid-acting insulin analog
  • Patients having a HbA1c of 8% or higher despite using an insulin pump for at least 6 months
  • Patients performing glucose self-monitoring four or more times per day
  • Patients accepting the technology
  • Patients agreeing to use the system with activated loop mode at least 75% of the total time
  • Patients must be affiliated to any kind of social security
Not Eligible

You will not qualify if you...

  • Patients receiving a total daily insulin dose lower than 8 units
  • Patients with serious illness or treatments that may impair diabetes physiology or interfere with the device (e.g., iSGLT2, steroids, metformin)
  • Patients with severe uncorrected hearing or vision problems preventing proper use of the DBLG1 System
  • Patients unable to understand and follow all instructions regarding the device and the study
  • Patients planning repeated MRI, CT scans, or high-frequency electrical heat treatments during the study year
  • Patients unwilling or unable to maintain contact with healthcare professionals
  • Patients who want to use insulin types other than 100 U/mL rapid-acting insulin analog with the system

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

Hôpital Avicenne APHP

Bobigny, France, 93000

Not Yet Recruiting

2

Hôpital de la cavale blanche

Brest, France, 29200

Not Yet Recruiting

3

CHU Caen

Caen, France, 14000

Actively Recruiting

4

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, France, 91100

Not Yet Recruiting

5

CHU Bocage Central

Dijon, France, 21079

Actively Recruiting

6

Hôpital Simone Veil

Eaubonne, France, 95600

Not Yet Recruiting

7

CHU Grenoble

Grenoble, France, 38000

Actively Recruiting

8

Groupe Hospitalier La Rochelle - Ré - Aunis

La Rochelle, France, 17019

Actively Recruiting

9

CHU Lille

Lille, France, 59037

Not Yet Recruiting

10

Diab-e-Care

Lyon, France, 69008

Not Yet Recruiting

11

Hôpital Européen

Marseille, France, 13003

Not Yet Recruiting

12

Hôpital la conception, pole ENDO

Marseille, France, 13385

Not Yet Recruiting

13

hôpital Nord Laennec

Nantes, France, 44093

Actively Recruiting

14

Lariboisière - Fernand Widal APHP

Paris, France, 75010

Not Yet Recruiting

15

Hôpital Bichet Claude Bernard - APHP

Paris, France, 75018

Not Yet Recruiting

16

Clinique Princess

Pau, France, 64000

Not Yet Recruiting

17

CHU Reims

Reims, France, 51100

Actively Recruiting

18

Hôpital Pontchaillou

Rennes, France, 35000

Actively Recruiting

19

Hôpital civil de Strasbourg

Strasbourg, France, 67000

Actively Recruiting

20

Hôpital de Rangueil

Toulouse, France, 31400

Not Yet Recruiting

Loading map...

Research Team

M

Marion Chassouant

CONTACT

E

Erik Huneker

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Observational Study of the Use of DBLG1 System in Real Life | DecenTrialz